Serbia Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Serbia Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Serbia Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The Serbian pharmaceutical and healthcare market represents a challenging environment for foreign drugmakers. Government cost containment, implemented through severe drug price cuts by the RFZO, will dampen growth. Furthermore, an increasing reliance on private health spending will impact pharmaceutical sales as the worsening macroeconomic outlook will reduce consumer spending power.

Headline Expenditure Projections

Pharmaceuticals: RSD92.43bn (USD1.05bn) in 2014 to RSD91.42bn (USD820mn) in 2015; -1.1% in local currency terms and -21.5% in US dollar terms. Forecast unchanged from Q 4 15.

Healthcare: RSD389.48bn (USD4.40bn) in 2014 to RSD384.91bn (USD3.45bn) in 2015; -1.2% in local currency terms and -21.6% in US dollar terms. Forecasts unchanged from Q 4 15 .

Headline Pharmaceuticals & Healthcare Forecasts (Serbia 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 1.066 1.045 0.820 0.786 0.815 0.867 0.932
Pharmaceutical sales, % of GDP 2.29 2.13 2.09 1.97 1.88 1.76 1.69
Pharmaceutical sales, % of health expenditure 23.7 23.7 23.8 23.9 24.2 24.6 25.0
Health spending, USDbn 4.502 4.404 3.454 3.296 3.363 3.522 3.724

Risk/Reward Index

Serbia's Pharmaceutical RRI score for Q415 is 39.7 out of 100, making it the 18th most attractive pharmaceutical market in Central and Eastern Europe. This is a decline compared to Q415, where it was ranked 15th with a score of 43.3. The decline is primarily the result of the depreciation of the Serbian dinar against the US dollar and the subsequent impact of that on market values and growth rates as measured in US dollar terms. The country's overall score remains below the regional average of 49.6.

Latest Updates

  • In December 2015, the Serbian economy minister announced new plans for the privatisation of state-owned pharmaceutical firm, Galenika. It is hoped to be completed by May 2016.

  • In November 2015, the Serbian government agreed to invest in health care institutions, in order to provide a better quality of healthcare services.

  • In October 2015, the Serbian government's new regulations regarding drug pricing took effect.

BMI Economic View

The Serbian government's fiscal consolidation drive will continue over the coming quarters. Although politically popular, the government will remain committed to cutting public sector wages and pensions to adhere to IMF loan conditions.

BMI Political View

Serbia's social stability will deteriorate in the coming months, and has prompted us to revise down our short-term political risk index for the country. Nevertheless, social instability will not result in the ousting of Prime Minister Aleksandar Vucic's cabinet, which will remain in power for the duration of its term ending in 2018. The ongoing migrant crisis is a cause for concern, placing strain on domestic and region-wide political relations.

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Serbia 2011-2019)
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2011-2019)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Serbia 2011-2019)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Serbia 2011-2019)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Serbia 2011-2019)
26
OTC Medicines Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Serbia 2011-2019)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Serbia 2013-2019)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Serbia 2013-2019)
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
Industry Risk Reward Index
35
Central And Eastern Europe Risk/Reward Index - Q4 2015
35
Serbia Risk/Reward Index
41
Rewards
41
Risks
41
Market Overview
43
Industry Trends And Developments
45
Epidemiology
45
Table: Serbian Cancer Incidence Rates, 2012-2035
47
Healthcare Sector
48
Healthcare Insurance
50
Table: Healthcare Resources (Serbia 2009-2014)
51
Table: Healthcare Personnel (Serbia 2009-2014)
51
Table: Healthcare Activity (Serbia 2009-2014)
52
Research & Development
52
Clinical Trials
53
Regulatory Development
55
Registration Renewals
57
Intellectual Property Environment
58
Promotion
60
Pricing Regime
63
Pricing & Reimbursement Developments
64
Reimbursement Regime
64
Reimbursement Developments
65
Competitive Landscape
66
Research-Based Industry
66
Generic Drugmakers
66
Company Activity
67
Pharmaceutical Wholesale And Retail
67
Company Profile
68
Galenika
68
GlaxoSmithKline
72
Hemofarm (Stada)
75
Krka
79
Merck
82
Novartis
84
Pfizer
86
Sanofi
88
Zdravlje Actavis
90
Demographic Forecast
94
Table: Population Headline Indicators (Serbia 1990-2025)
95
Table: Population By Age Group (Serbia 1990-2025)
95
Table: Population By Age Group % (Serbia 1990-2025)
96
Glossary
98
Methodology
100
Pharmaceutical Expenditure Forecast Model
100
Healthcare Expenditure Forecast Model
100
Notes On Methodology
101
Risk/Reward Index Methodology
102
Index Overview
103
Table: Pharmaceutical Risk/Reward Index Indicators
103
Indicator Weightings
104

The Serbia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Serbia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Serbia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Serbia, to test other views - a key input for successful budgeting and strategic business planning in the Serbian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Serbian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Serbia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.